Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01949506
Official study title

(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas

Study summary

This is a prospective study to document the local control rates with SBRT specifically for pulmonary metastases from soft tissue sarcoma. This study will prospectively document acute and late toxicity, quality of life (QoL), tumor control, and survival.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSBRT

The study team can explain what participation involves.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 28, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Medical College of Wisconsin

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Medical College of Wisconsin
Interventions being studied
Radiation: SBRT
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Metastatic or stage IV→
Treatment approach
Radiation therapy→
Study topics
Survivorship and quality of life→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • ≥18 years of age
  • Pathologic confirmation of primary soft tissue sarcoma with pathologic or radiographic evidence of pulmonary metastatic disease
  • No evidence of extra pulmonary progression of disease for 3 months prior to enrollment on study
  • 1-5 pulmonary lesions all ≤5 cm in size
  • Medically inoperable or declines surgery
  • Patients may have had previous treatment for pulmonary metastases
Reasons someone may not be able to joinExclusion criteria
  • Patients who have uncontrolled extra-pulmonary disease
  • Pregnant women
  • Patients who have greater than 5 pulmonary lesions at the time of study enrollment
  • Patients who have disease progression outside the lungs within 3 months of enrollment on the study
  • Disease pathology other than sarcoma subtypes
  • Patients with a history of metastatic disease from a primary other than sarcoma

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Froedtert Hospital and Medical College of WisconsinMilwaukee, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 28, 2023. Always confirm current availability with the study team.

View original record ↗